IGMPI India

Indian Drug Manufacturers Association (IDMA) ties up with global safety science company UL for providing the pharma industry with tools and training to meet the increased compliance levels and to decrease the complex regulatory issues.

The managing director of UL India and South Asia said that Given the rapid growth curve of the Indian pharmaceutical industry, it is quite natural that the spotlight is on Indian companies adherence to good manufacturing practices. We need to look at this increased regulatory scrutiny more as an opportunity for them. This calls for a universal understanding of good manufacturing practices (GMP) guidelines, rightful implementation and fool proof audit processes to ensure consistency.

The global strategic head of UL said that UL aims at becoming an industry partner for all companies looking to standardise their GMP practices, appropriate documentation and management visibility to training compliance.

Through this tie up, IDMA and UL are also hosting a summit to share best practices and trends in critical areas including GMP (Good Manufacturing Practices), CGMP (Current GMP), GCP (Good Clinical Practices), BiMo (Bio-medical research), Quality System Regulation (QSR), US FDA and regulatory compliance. Ul will offer learning and training to pharma companies, especially in the wake of increased scrutiny by global regulators on Indian pharmaceutical companies.